New Drug Reduces Recurrence Risk for Some Women With Early-Stage Breast Cancer
Research presented at the San Antonio Breast Cancer Symposium may result in a new standard of care for some people with HER2 positive, early stage breast cancer.
FDA Approves First Biosimilar for Non-Hodgkin Lymphoma
The US Food and Drug Administration (FDA) has approved Truxima (rituximab-abbs), the first biosimilar drug to treat adults with some types of non-Hodgkin lymphoma.
Six Plan-ahead Tips to Party Smarter
Have a jolly, festive time at holiday parties this month while sticking to your healthy eating goals. Follow our tips to enjoy the season without having to pay for it later.
Nurture Your Emotional Health
Taking care of yourself emotionally can help you feel better and work better. Find out what you can do to stay positive and happy.
FDA Approves Vitrakvi (Larotrectinib) for Tumors With Certain Genetic Change
For the second time, the US Food and Drug Administration (FDA) has approved a drug to treat tumors with a specific genetic change regardless of the type of cancer. Vitrakvi (larotrectinib) is for adults and children with solid tumors that test positive for NTRK genes, which can help cancerous tumors grow.
Can Coffee Lower Cancer Risk?
What’s the latest about the health effects of that morning-boosting, belly-warming cup of rich, creamy coffee? We’ll tell you what the research says about coffee and your cancer risk.
FDA Approves 2 Drugs for Acute Myeloid Leukemia (AML)
The US Food and Drug Administration (FDA) has approved 2 new drugs, Daurismo (glasdegib) and Venclexta (venetoclax), to treat people newly diagnosed with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy.
FDA Proposes Regulations as Teen E-Cigarette Use Skyrockets 78% in 1 Year
Use of e-cigarettes (also known as vaping) by high school students has jumped 78% since last year, according to the US Centers for Disease Control and Prevention (CDC).
